Gotowe bibliografie tematyczne / Low molecular weight heparin / Artykuły w czasopismach

Artykuły w czasopismach na temat „Low molecular weight heparin”

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Low molecular weight heparin.
Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 10 marca 2023

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Low molecular weight heparin”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

&NA;. "Heparin/low molecular weight heparins". Reactions Weekly &NA;, nr 1414 (sierpień 2012): 28–29. http://dx.doi.org/10.2165/00128415-201214140-00091.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

&NA;. "Heparin/low-molecular-weight heparins". Reactions Weekly &NA;, nr 1198 (kwiecień 2008): 22. http://dx.doi.org/10.2165/00128415-200811980-00068.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

&NA;. "Heparin/low molecular weight heparins". Reactions Weekly &NA;, nr 1210 (lipiec 2008): 18. http://dx.doi.org/10.2165/00128415-200812100-00051.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

&NA;. "Heparin/low molecular weight heparins". Reactions Weekly &NA;, nr 1211 (lipiec 2008): 17–18. http://dx.doi.org/10.2165/00128415-200812110-00053.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

&NA;. "Heparin/low molecular weight heparins". Reactions Weekly &NA;, nr 1211 (lipiec 2008): 18. http://dx.doi.org/10.2165/00128415-200812110-00056.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

&NA;. "Heparin/low molecular weight heparins". Reactions Weekly &NA;, nr 1277 (listopad 2009): 23. http://dx.doi.org/10.2165/00128415-200912770-00068.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

&NA;. "Heparin/low molecular weight heparins". Reactions Weekly &NA;, nr 1231 (grudzień 2008): 16–17. http://dx.doi.org/10.2165/00128415-200812310-00049.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

&NA;. "Heparin/low molecular weight heparins". Reactions Weekly &NA;, nr 989 (luty 2004): 10. http://dx.doi.org/10.2165/00128415-200409890-00030.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Mulloy, Barbara, Trevor Barrowcliffe i Elaine Gray. "Heparin and low-molecular-weight heparin". Thrombosis and Haemostasis 99, nr 11 (2008): 807–18. http://dx.doi.org/10.1160/th08-01-0032.

Pełny tekst źródła
Streszczenie:
SummaryHeparin is one of the oldest biological medicines, and has an established place in the prevention and treatment of venous thrombosis. Low-molecular-weight heparins (LMWH) have been developed by several manufacturers and have advantages in terms of pharmacokinetics and convenience of administration. They have been shown to be at least as effective and safe as unfractionated heparin and have replaced the latter in many indications. In this article the chemistry, mechanisms of action, measurement of anticoagulant activities, and clinical status of heparin and LMWH are reviewed.
Style APA, Harvard, Vancouver, ISO itp.
10

Hoppensteadt, Debra, Jeanine M. Walenga, Jawed Fareed i Rodger L. Bick. "Heparin, low–molecular-weight heparins, and heparin pentasaccharide". Hematology/Oncology Clinics of North America 17, nr 1 (luty 2003): 313–41. http://dx.doi.org/10.1016/s0889-8588(02)00091-6.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
11

&NA;. "Heparin/low molecular weight heparins/warfarin". Reactions Weekly &NA;, nr 1321 (październik 2010): 20. http://dx.doi.org/10.2165/00128415-201013210-00061.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
12

Hirsh, Jack. "Heparin and low-molecular weight heparins". Coronary Artery Disease 3, nr 11 (listopad 1992): 990–1002. http://dx.doi.org/10.1097/00019501-199211000-00002.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
13

&NA;. "Heparin/low-molecular weight heparin". Reactions Weekly &NA;, nr 1216 (sierpień 2008): 19. http://dx.doi.org/10.2165/00128415-200812160-00049.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
14

Mulloy, B., C. Gee, S. F. Wheeler, R. Wait, E. Gray i T. W. Barrowcliffe. "Molecular Weight Measurements of Low Molecular Weight Heparins by Gel Permeation Chromatography". Thrombosis and Haemostasis 77, nr 04 (1997): 668–74. http://dx.doi.org/10.1055/s-0038-1656031.

Pełny tekst źródła
Streszczenie:
SummaryThe molecular weight profiles of low molecular weight heparin samples have been measured by high-performance gel permeation chromatography using as calibrant the heparinase-degraded material (90/686) now established as the 1st International Reference Preparation (IRP) Low Molecular Weight Heparin for Molecular Weight Calibration. Use of the calibrant as a broad molecular weight standard is described and a calibration table provided based on data collected over several years in one laboratory.In order to confirm the assignment of degree of polymerisation to resolved oligosaccharide peaks in the calibrant, molecular weights of oligosaccharides fractionated from the 1st IRP were independently determined by fast atom bombardment mass spectrometry (FAB MS).The molecular weight distributions of commercial low molecular weight heparins have been characterized. Measurements of molecular weight parameters of heparin molecular weight standards from several sources provide comparisons between the molecular weight scales of this and other studies.
Style APA, Harvard, Vancouver, ISO itp.
15

Martinez-Salas, José, Richard Mendelssohn, William M. Abraham, Bernard Hsiao i Tahir Ahmed. "Inhibition of allergic airway responses by inhaled low-molecular-weight heparins: molecular-weight dependence". Journal of Applied Physiology 84, nr 1 (1.01.1998): 222–28. http://dx.doi.org/10.1152/jappl.1998.84.1.222.

Pełny tekst źródła
Streszczenie:
Martinez-Salas, José, Richard Mendelssohn, William M. Abraham, Bernard Hsiao, and Tahir Ahmed. Inhibition of allergic airway responses by inhaled low-molecular-weight heparins: molecular-weight dependence. J. Appl. Physiol. 84(1): 222–228, 1998.—Inhaled heparin prevents antigen-induced bronchoconstriction and inhibits anti-immunoglobulin E-mediated mast cell degranulation. We hypothesized that the antiallergic action of heparin may be molecular weight dependent. Therefore, we studied the effects of three different low-molecular-weight fractions of heparin [medium-, low-, and ultralow-molecular-weight heparin (MMWH, LMWH, ULMWH, respectively)] on the antigen-induced acute bronchoconstrictor response (ABR) and airway hyperresponsiveness (AHR) in allergic sheep. Specific lung resistance was measured in 22 sheep before and after airway challenge with Ascaris suum antigen, without and after pretreatment with inhaled fractionated heparins at doses of 0.31–5.0 mg/kg. Airway responsiveness was estimated before and 2 h postantigen as the cumulative provocating dose of carbachol in breath units that increased specific lung resistance by 400%. All fractionated heparins caused a dose-dependent inhibition of ABR and AHR. ULMWH was the most effective fraction, with the inhibitory dose causing 50% protection (ID50) against ABR of 0.5 mg/kg, whereas ID50values of LMWH and MMWH were 1.25 and 1.8 mg/kg, respectively. ULMWH was also the most effective fraction in attenuating AHR; the ID50values for ULMWH, LMWH, and MMWH were 0.5, 2.5, and 4.7 mg/kg, respectively. These data suggest that 1) fractionated low-molecular-weight heparins attenuate antigen-induced ABR and AHR; 2) there is an inverse relationship between the antiallergic activity of heparin fractions and molecular weight; and 3) ULMWH is the most effective fraction preventing allergic bronchoconstriction and airway hyperresponsiveness.
Style APA, Harvard, Vancouver, ISO itp.
16

&NA;. "Danaparoid sodium/heparin/low molecular weight heparins". Reactions Weekly &NA;, nr 1269 (wrzesień 2009): 15–16. http://dx.doi.org/10.2165/00128415-200912690-00042.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
17

&NA;. "Low molecular weight heparins challenge standard heparin". Inpharma Weekly &NA;, nr 805 (wrzesień 1991): 22–23. http://dx.doi.org/10.2165/00128413-199108050-00057.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
18

Hirsh, Jack, i Robert Raschke. "Heparin and Low-Molecular-Weight Heparin". Chest 126, nr 3 (wrzesień 2004): 188S—203S. http://dx.doi.org/10.1378/chest.126.3_suppl.188s.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
19

Hirsh, Jack, Theodore E. Warkentin, Robert Raschke, Christopher Granger, E. Magnus Ohman i James E. Dalen. "Heparin and Low-Molecular-Weight Heparin". Chest 114, nr 5 (listopad 1998): 489S—510S. http://dx.doi.org/10.1378/chest.114.5_supplement.489s.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
20

&NA;. "Low molecular weight heparin". Reactions Weekly &NA;, nr 1148 (kwiecień 2007): 25. http://dx.doi.org/10.2165/00128415-200711480-00081.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
21

Whang, Peter G., i Jay R. Lieberman. "Low-Molecular-Weight Heparin". Journal of the American Academy of Orthopaedic Surgeons 10, nr 5 (wrzesień 2002): 299–302. http://dx.doi.org/10.5435/00124635-200209000-00001.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
22

&NA;. "Low-molecular-weight heparin". Reactions Weekly &NA;, nr 683 (styczeń 1998): 10. http://dx.doi.org/10.2165/00128415-199806830-00027.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
23

&NA;. "Low molecular weight heparin". Reactions Weekly &NA;, nr 378 (listopad 1991): 6. http://dx.doi.org/10.2165/00128415-199103780-00028.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
24

&NA;. "Low molecular weight heparin". Reactions Weekly &NA;, nr 417 (wrzesień 1992): 10. http://dx.doi.org/10.2165/00128415-199204170-00038.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
25

&NA;. "Low molecular weight heparin". Reactions Weekly &NA;, nr 341 (marzec 1991): 7. http://dx.doi.org/10.2165/00128415-199103410-00040.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
26

&NA;. "Low molecular weight heparin". Reactions Weekly &NA;, nr 357 (czerwiec 1991): 8. http://dx.doi.org/10.2165/00128415-199103570-00035.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
27

Hirsh, J., i MN Levine. "Low molecular weight heparin". Blood 79, nr 1 (1.01.1992): 1–17. http://dx.doi.org/10.1182/blood.v79.1.1.1.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
28

Hirsh, J., i MN Levine. "Low molecular weight heparin". Blood 79, nr 1 (1.01.1992): 1–17. http://dx.doi.org/10.1182/blood.v79.1.1.bloodjournal7911.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
29

Hirsh, Jack. "Low Molecular Weight Heparin". Thrombosis and Haemostasis 70, nr 01 (1993): 204–7. http://dx.doi.org/10.1055/s-0038-1646191.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
30

Hirsh, Jack. "Low-Molecular-Weight Heparin". Circulation 98, nr 15 (13.10.1998): 1575–82. http://dx.doi.org/10.1161/01.cir.98.15.1575.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
31

Heit, John A. "Low-Molecular-Weight Heparin". Regional Anesthesia and Pain Medicine 23, Sup 2 (listopad 1998): 135–39. http://dx.doi.org/10.1097/00115550-199823062-00002.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
32

Routledge, P. A., i R. R. West. "Low molecular weight heparin." BMJ 305, nr 6859 (17.10.1992): 906. http://dx.doi.org/10.1136/bmj.305.6859.906.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
33

Horlocker, Terese T., i John A. Heit. "Low Molecular Weight Heparin". Anesthesia & Analgesia 85, nr 4 (październik 1997): 874–85. http://dx.doi.org/10.1097/00000539-199710000-00031.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
34

Hunt, B. J. "Low Molecular Weight Heparin". Blood Coagulation & Fibrinolysis 3, nr 5 (październik 1992): 683. http://dx.doi.org/10.1097/00001721-199210000-00030.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
35

Schmitt, Y., i H. Schneider. "Low molecular weight heparin". Blood Coagulation & Fibrinolysis 7, nr 3 (kwiecień 1996): 385. http://dx.doi.org/10.1097/00001721-199604000-00051.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
36

Horlocker, Terese T., i John A. Heit. "Low Molecular Weight Heparin". Anesthesia & Analgesia 85, nr 4 (październik 1997): 874–85. http://dx.doi.org/10.1213/00000539-199710000-00031.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
37

Wolf, Helmut. "Low-molecular-weight heparin". Medical Clinics of North America 78, nr 3 (maj 1994): 733–43. http://dx.doi.org/10.1016/s0025-7125(16)30155-9.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
38

Nunnelee, Janice D. "Low-molecular-weight heparin". Journal of Vascular Nursing 15, nr 3 (wrzesień 1997): 94–96. http://dx.doi.org/10.1016/s1062-0303(97)90057-1.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
39

Vanpee, Dominique, Jean-Bernard Gillet i Christian Swine. "Low Molecular Weight Heparin". Annals of Emergency Medicine 36, nr 3 (wrzesień 2000): 277. http://dx.doi.org/10.1067/mem.2000.109264.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
40

Salzman, Edwin W. "Low-Molecular-Weight Heparin". New England Journal of Medicine 315, nr 15 (9.10.1986): 957–59. http://dx.doi.org/10.1056/nejm198610093151509.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
41

Gough, S. "Low molecular weight heparin." BMJ 303, nr 6805 (28.09.1991): 784. http://dx.doi.org/10.1136/bmj.303.6805.784-a.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
42

Brack, M. J. "Low molecular weight heparin". International Journal of Cardiology 38, nr 2 (luty 1993): 207–8. http://dx.doi.org/10.1016/0167-5273(93)90193-k.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
43

Barrowcliffe, T. W., A. D. Curtis, E. A. Johnson i D. P. Thomas. "An International Standard for Low Molecular Weight Heparin". Thrombosis and Haemostasis 60, nr 01 (1988): 001–7. http://dx.doi.org/10.1055/s-0038-1647623.

Pełny tekst źródła
Streszczenie:
SummaryAn international collaborative study has been carried out with the aim of establishing an international standard for low molecular weight (LMW) heparin. Three preparations of LMW heparin were assayed against the International Standard for unfractionated heparin (UFH) by 25 laboratories in 13 countries, using nine different assay methods. The results confirmed previous findings of non-parallel assays, wide interlaboratory variability and differences between methods when LMW heparins are assayed against a UFH standard. Use of one of the LMW heparins as a standard for the other two gave parallel assays and much closer agreement between laboratories. The preparation in ampoules coded 85/600 was selected as likely to give the best agreement with the largest number of LMW heparins; potencies were assigned by taking the mean of all the anti-Xa assays, and the mean of the thrombin and APTT assays, to represent the two major groups of activities. Preparation 85/600 has been established by WHO as the 1st International Standard for LMW heparin, with potencies of 1,680 iu/ampoule by anti-Xa assays and 665 iu/ampoule by thrombin inhibition and APTT assays.
Style APA, Harvard, Vancouver, ISO itp.
44

Chen, Jianle, Yanlei Yu, Jawed Fareed, Debra Hoppensteadt, Walter Jeske, Ahmed Kouta, Caijuan Jin i in. "Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin". Clinical and Applied Thrombosis/Hemostasis 25 (1.01.2019): 107602961984070. http://dx.doi.org/10.1177/1076029619840701.

Pełny tekst źródła
Streszczenie:
Heparin and its low-molecular-weight heparin derivatives are widely used clinical anticoagulants. These drugs are critical for the practice of medicine in applications, including kidney dialysis, cardiopulmonary bypass, and in the management of venous thromboembolism. Currently, these drugs are derived from livestock, primarily porcine intestine and less frequently bovine intestine and bovine lung. The worldwide dependence on the pig as a single dominant animal species has made the supply chain for this critical drug quite fragile, leading to the search for other sources of these drugs, including the expanded use of bovine tissues. A number of laboratories are now also examining the similarities between heparin and low-molecular-weight heparins prepared from porcine and ovine tissues. This study was designed to compare low-molecular-weight heparin prepared from ovine heparin through chemical β-elimination, a process currently used to prepare the low-molecular-weight heparin, enoxaparin. Using top-down, bottom-up, and compositional analyses as well as bioassays, low-molecular-weight heparin derived from ovine intestine was shown to closely resemble enoxaparin. Moreover, the compositions of daughter low-molecular-weight heparins prepared from three unfractionated ovine parent heparins were compared. Ovine enoxaparins had similar molecular weight and in vitro anticoagulant activities as Lovenox. Some disaccharide compositional, oligosaccharide composition at the reducing and nonreducing ends and intact chain compositional differences could be observed between porcine enoxaparin and ovine low-molecular-weight heparin. The similarity of these ovine and porcine heparin products suggests that their preclinical evaluation and ultimately clinical assessment is warranted.
Style APA, Harvard, Vancouver, ISO itp.
45

Fareed, Jawed, Walter Jeske, Daniel Fareed, Melaine Clark, Rakesh Wahi, Cafer Adiguzel i Debra Hoppensteadt. "Are All Low Molecular Weight Heparins Equivalent in the Management of Venous Thromboembolism?" Clinical and Applied Thrombosis/Hemostasis 14, nr 4 (26.12.2007): 385–92. http://dx.doi.org/10.1177/1076029608319881.

Pełny tekst źródła
Streszczenie:
Low molecular weight heparins are replacing unfractionated heparin in a number of clinical indications because of their improved subcutaneous bioavailability and more predictable antithrombotic response. Clinical trials have demonstrated that low molecular weight heparins are at least as safe and effective as unfractionated heparin for the initial treatment of venous thromboembolism, and unfractionated heparin and warfarin for primary and secondary thromboprophylaxis. The mechanism behind the antithrombotic action of low molecular weight heparins is not fully understood but is likely to involve inhibition of coagulation factors Xa and IIa (thrombin), release of tissue-factor-pathway inhibitor, and inhibition of thrombin activatable fibrinolytic inhibitor. Different low molecular weight heparins have been shown to have various effects on coagulation parameters. Seven low molecular weight heparins are currently marketed worldwide, each demonstrated distinct chemical entities with unique pharmacokinetic and pharmacodynamic profiles. Each low molecular weight heparin is approved for specific indications based on the available efficacy and safety data for that product. The relative efficacy and safety of the low molecular weight heparins are unclear because there have been very few direct comparisons in randomized clinical trials. While recommending low molecular weight heparins for the prevention and treatment of venous thromboembolism, clinical guidelines have not specified individual agents. National and international organizations recognize that low molecular weight heparins are distinct entities and that they should not be used interchangeably in clinical practice. Each low molecular weight heparin should be used at the recommended dose when efficacy and safety data exist for the condition being treated. When these data are not available, the dosing and administration of low molecular weight heparins must be adapted from existing data and recommendations.
Style APA, Harvard, Vancouver, ISO itp.
46

Barrowcliffe, T. W., A. D. Curtis, T. P. Tomlinson, A. R. Hubbard, E. A. Johnson i D. P. Thomas. "Standardization of Low Molecular Weight Heparins : A Collaborative Study". Thrombosis and Haemostasis 54, nr 03 (1985): 675–79. http://dx.doi.org/10.1055/s-0038-1660095.

Pełny tekst źródła
Streszczenie:
SummaryA collaborative study was carried out, in which eight laboratories each assayed eight low molecular weight (LMW) heparins against the International Standard (IS) for heparin. APTT assays and three types of anti-Xa method were used. The results of this study showed that:1. LMW heparins cannot be validly assayed against the IS by APTT or anti-Xa methods.2. Potencies of LMW heparins vs. the IS differed considerably between the four types of assay method used and also between different laboratories using the same type of method.3. Adoption of a single LMW heparin standard would improve validity, improve inter-laboratory variation, and largely abolish the differences between the three types of anti-Xa method. However, since calibration of a LMW heparin standard against the IS would give potencies that differ widely by the different assay methods, a single assay method such as the anti-Xa amidolytic, plasma, would need to be chosen for this calibration.
Style APA, Harvard, Vancouver, ISO itp.
47

Mammen, Eberhard F. "Low Molecular Weight Heparins and Heparin-Induced Thrombocytopenia". Clinical and Applied Thrombosis/Hemostasis 5, nr 1_suppl (październik 1999): S72—S75. http://dx.doi.org/10.1177/10760296990050s113.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
48

Ambrosioni, E., i E. Strocchi. "Pharmacokinetics of Heparin and Low Molecular Weight Heparins". Pathophysiology of Haemostasis and Thrombosis 20, nr 1 (1990): 94–97. http://dx.doi.org/10.1159/000216165.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
49

Stefoni, Sergio, Giuseppe Cianciolo, Gabriele Donati, Luigi Colì, Gaetano La Manna, Concettina Raimondi, Vittorio Dalmastri, Valentina Orlandi i Francesca D’Addio. "Standard Heparin versus Low-Molecular-Weight Heparin". Nephron 92, nr 3 (2002): 589–600. http://dx.doi.org/10.1159/000064086.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
50

Raskob, Gary E. "Low molecular weight heparin, heparin, and warfarin". Current Opinion in Hematology 2, nr 5 (1995): 372–79. http://dx.doi.org/10.1097/00062752-199502050-00008.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany bibliografiami na temat „Low molecular weight heparin” dla innych typów źródeł:
Rozprawy doktorskie Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii